Why CGRP Drugs Became First Line for Migraine Prevention

In one sentence#

A person with frequent migraine no longer has to fail two or three older prevention pills before a CGRP-targeting medicine is considered reasonable. In a March 2024 position statement in Headache: The Journal of Head and Face Pain, the American Headache Society (AHS) placed CGRP therapies among the first-line choices for migraine prevention, dropping the long-standing expectation that patients try older drugs first. The society based that call on more than a decade of trial results plus real-world experience since these drugs first reached patients in 2018. What follows explains what the statement says and why.

Key points#

• The AHS position statement (published March 11, 2024) makes CGRP-targeting therapies a first-line option for preventing migraine.
• The change removes any blanket "fail older drugs first" requirement, a practice known as step therapy.
• Two drug families are involved: injected or infused monoclonal antibodies, and oral gepants.
• The argument rests less on being far stronger than older drugs and more on the whole package of benefit, tolerability, and safety.
• A position statement is a professional reference, not an insurance rule, so cost and coverage still shape real decisions.

The habit the statement was written to change#

For years, a patient who wanted a migraine preventive met a familiar sequence. Start with an older, inexpensive pill borrowed from another field of medicine. If it did not help, or the side effects were too much, try a second. Only after two or more of these had failed would a newer CGRP medicine be considered. This "try the cheap ones first" ladder is called step therapy, and it was baked into both prescribing habits and insurance coverage.

The 2024 statement takes direct aim at that ladder. Its central line is that CGRP-targeting treatments belong alongside the other first-line options "without a requirement for prior failure of other classes of migraine preventive treatment." In other words, the accumulated evidence no longer supports forcing everyone down the ladder before reaching these drugs. The statement was issued by the American Headache Society and authored by Charles, Digre, Goadsby, Robbins, and Hershey.

What counts as a CGRP therapy#

Two groups sit under the CGRP label, and they reach the body in different ways.

The first group is the monoclonal antibodies, large proteins given by injection or infusion that either soak up CGRP or block its receptor. These include erenumab, fremanezumab, galcanezumab, and eptinezumab. The second group is the gepants, small molecules taken as pills that block the CGRP receptor. Rimegepant and atogepant carry preventive indications. The society describes all of these as "migraine-specific," a point worth pausing on.

Why "migraine-specific" is the whole idea#

CGRP, or calcitonin gene-related peptide, is a signaling molecule released around the trigeminal nerve during a migraine attack. It widens blood vessels in the head and helps carry pain signals, and its levels climb while an attack is underway. Block CGRP or the receptor it lands on, and you interrupt that chain at a step that appears central to migraine itself.

That is a genuine departure from how older preventives came to be used. Most of them were designed for something else and were only later noticed to cut migraine frequency. Some blood-pressure beta-blockers, the seizure drugs topiramate and valproate, the antidepressant amitriptyline, and onabotulinumtoxinA all fit this pattern. They can work well, but each arrives carrying a side-effect profile from its original job. The CGRP agents were built around migraine biology from the start.

The evidence: benefit, tolerability, and safety together#

It would be a misreading to think the society declared CGRP drugs dramatically stronger than everything else. In head-to-head attack reduction, that is not the claim. The case is instead about the full balance of three things.

On benefit, the AHS drew on the randomized trials behind FDA approval across both episodic and chronic migraine, plus real-world groups of patients followed since 2018.

On tolerability, the newer drugs pull ahead in ordinary practice. Older oral preventives often fail not because they cannot reduce attacks but because people cannot stay on them. Topiramate is a clear example: it needs slow dose increases and frequently causes mental fog, tingling, and other effects that force people to quit. The statement highlights how poorly the older pills are sustained, citing commercial-claims data showing that only about 17 to 20 percent of patients were still taking their standard oral preventive at one year. In one head-to-head trial it references, far fewer patients stopped a CGRP antibody for side effects than stopped topiramate. The consistent direction of that signal, not one headline number, is the point.

On safety, the CGRP agents avoid some of the specific liabilities that limit older options, such as the birth-defect and cognitive concerns tied to certain seizure medicines. Their most common problems are comparatively minor: constipation and injection-site reactions for the antibodies, with generally low rates of serious events across the class. Several years of monitoring since 2018 is part of why the society felt able to revise its guidance, though watching any newer therapy is an ongoing task.

The cost question, handled openly#

The statement does not pretend price is a non-issue. CGRP therapies cost more per dose than generic oral pills, and it says so. What it does is reframe the arithmetic. The society urges that decisions not rest "solely on the cost of treatment," and asks clinicians and payers to weigh what happens downstream: less use of acute rescue medication, fewer emergency visits, and better work productivity with less absence. A treatment that people actually tolerate and keep taking can lower the total cost of care even when the drug itself is pricier.

This is also where the limits of a position statement show. It cannot rewrite a single insurer's formulary. What it gives you and your clinician is a credible professional reference to point to when a step-therapy rule stands between you and a treatment the evidence supports as first line.

Reading this in proportion#

A few cautions keep the change in scale. First line does not mean first choice for everyone. The statement puts CGRP therapies among the first-line options, not above them, and route of administration, pregnancy plans, other conditions, and individual response all still matter. The adherence and discontinuation figures come from claims and observational data, which carry their own limits, and some people stop a drug because they got better rather than because it failed. The strength of the conclusion comes from convergence: trial benefit, a cleaner tolerability signal, and post-approval safety data all pointing the same way. That alignment is what let a specialty society move an entire drug class from later line to first line in one update.